Advertisement

Molecular Biology Reports

, Volume 41, Issue 5, pp 3127–3133 | Cite as

Associations between C1431T and Pro12Ala variants of PPARγ gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population

  • Hassan Rooki
  • Monir-sadat Haerian
  • Pedram Azimzadeh
  • Reza Mirhafez
  • Mahmoud Ebrahimi
  • Gordon Ferns
  • Majid Ghayour-Mobarhan
  • Mohammad-Reza Zali
Article

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear hormone receptor that regulates a number of genes involved in lipid and carbohydrate metabolism. The aim of this study was to investigate the association of C1431T and Pro12Ala polymorphisms of PPARγ gene and their haplotypes and diplotypes with risk of metabolic syndrome (MetS) in an Iranian population. A total of 340 unrelated Iranian subjects, including 175 MetS patients and 165 normal controls were enrolled. Each group was then divided into two subgroups according to the genotype (Pro/Pro and Pro/Ala + Ala/Ala for Pro12Ala, CC and CT + TT for C1431T). Genotypes were determined using a TaqMan method. Anthropometric indices, fasting plasma glucose and fasting lipid profile were measured by routine methods. A significant difference in the frequencies of the C1431T genotypes was observed between MetS and control subjects (P = 0.014), whereas no association was found for the Pro12Ala. The T allele carriers had a significantly increased risk of MetS compared to the CC genotype (P = 0.016) even after correction for multiple-testing and adjustment for age, sex and genotype. The T allele may therefore be considered as a risk factor for MetS (P = 0.003). Analysis of combined groups showed that X/Ala-CC and Pro/Pro-X/T diplotypes were associated with a higher body weight, waist circumference and waist to hip ratio among the individuals with MetS. Moreover the Ala-T haplotype was weakly associated with a higher level of triglyceride and lower level of HDL, suggesting the possibility of an interaction between Ala and T alleles. This study suggests that the PPARγ C1431T polymorphism is related to an increased risk of MetS in an Iranian population and interacts with the Pro12Ala polymorphism, further increasing the risk of MetS.

Keywords

Peroxisome proliferator-activated receptor-γ gene Metabolic syndrome Single nucleotide polymorphism 

Notes

Acknowledgments

We would like to thank all the study participants for their cooperation. This work was supported by Research Project No. 467, as a PhD thesis, financed by the Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences.

References

  1. 1.
    Denke MA, Pasternak RC (2001) Defining and treating the metabolic syndrome: a primer from the adult treatment panel III. Curr Treat Options Cardiovasc Med 3:251–253CrossRefPubMedGoogle Scholar
  2. 2.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–1428CrossRefPubMedGoogle Scholar
  3. 3.
    Bruce KD, Hanson MA (2010) The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr 140:648–652CrossRefPubMedGoogle Scholar
  4. 4.
    Gotoda T (2004) Genetic susceptibility to metabolic syndrome. Nihon Rinsho 62:1037–1044PubMedGoogle Scholar
  5. 5.
    Monda KL, North KE, Hunt SC, Rao DC, Province MA et al (2010) The genetics of obesity and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets 10:86–108CrossRefPubMedGoogle Scholar
  6. 6.
    Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I et al (2012) Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet 5:242–249PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649–688PubMedGoogle Scholar
  8. 8.
    Fajas L, Debril MB, Auwerx J (2001) Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1–9CrossRefPubMedGoogle Scholar
  9. 9.
    Meirhaeghe A, Amouyel P (2004) Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 83:93–102CrossRefPubMedGoogle Scholar
  10. 10.
    Yen CJ, Beamer BA, Negri C, Silver K, Brown KA et al (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241:270–274CrossRefPubMedGoogle Scholar
  11. 11.
    Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80CrossRefPubMedGoogle Scholar
  12. 12.
    Huguenin GV, Rosa G (2010) The Ala allele in the PPAR-gamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. Br J Nutr 104:488–497CrossRefPubMedGoogle Scholar
  13. 13.
    Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE et al (2004) Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 47:555–558CrossRefPubMedGoogle Scholar
  14. 14.
    Meshkani R, Taghikhani M, Larijani B, Bahrami Y, Khatami S et al (2007) Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPARgamma-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population. Clin Chem Lab Med 45:477–482CrossRefPubMedGoogle Scholar
  15. 15.
    Masud S, Ye S (2003) Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 40:773–780PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287CrossRefPubMedGoogle Scholar
  17. 17.
    Ostgren CJ, Lindblad U, Melander O, Melander A, Groop L et al (2003) Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project. J Hypertens 21:1657–1662CrossRefPubMedGoogle Scholar
  18. 18.
    Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK et al (2004) Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 45:674–685CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou X, Chen J, Xu W (2012) Association between C1431T polymorphism in peroxisome proliferator-activated receptor-gamma gene and coronary artery disease in Chinese Han population. Mol Biol Rep 39:1863–1868CrossRefPubMedGoogle Scholar
  20. 20.
    Wang XL, Oosterhof J, Duarte N (1999) Peroxisome proliferator-activated receptor gamma C161–>T polymorphism and coronary artery disease. Cardiovasc Res 44:588–594CrossRefPubMedGoogle Scholar
  21. 21.
    Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES et al (2006) Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch Med Res 37:86–94CrossRefPubMedGoogle Scholar
  22. 22.
    Shi H, Yu X, Li Q, Ye X, Gao Y et al (2012) Association between PPAR-gamma and RXR-alpha gene polymorphism and metabolic syndrome risk: a case-control study of a Chinese Han population. Arch Med Res 43:233–242CrossRefPubMedGoogle Scholar
  23. 23.
    Dongxia L, Qi H, Lisong L, Jincheng G (2008) Association of peroxisome proliferator-activated receptorgamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ J 72:551–557CrossRefPubMedGoogle Scholar
  24. 24.
    Doney A, Fischer B, Frew D, Cumming A, Flavell DM et al (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752CrossRefPubMedGoogle Scholar
  26. 26.
    Gaunt TR, Rodriguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’. BMC Bioinformatics 8:428PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Mirzaei H, Akrami SM, Golmohammadi T, Doosti M, Heshmat R et al (2009) Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor gamma2 gene in Iranian diabetic and obese subjects. Metab Syndr Relat Disord 7:453–458CrossRefPubMedGoogle Scholar
  28. 28.
    Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH (2011) Polymorphism of peroxisome proliferator-activated receptor gamma (PPARgamma) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. Eur J Pharmacol 671:1–6CrossRefPubMedGoogle Scholar
  29. 29.
    Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J (2005) Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes 54:3043–3048CrossRefPubMedGoogle Scholar
  30. 30.
    Gurnell M (2003) PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol (Oxf) 59:267–277CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Hassan Rooki
    • 1
    • 2
  • Monir-sadat Haerian
    • 1
  • Pedram Azimzadeh
    • 1
  • Reza Mirhafez
    • 2
  • Mahmoud Ebrahimi
    • 3
  • Gordon Ferns
    • 4
  • Majid Ghayour-Mobarhan
    • 2
    • 3
  • Mohammad-Reza Zali
    • 1
  1. 1.Gastroenterology and Liver Diseases Research CenterShahid Beheshti University of Medical SciencesTehranIran
  2. 2.Department of Modern Sciences and Technologies, School of MedicineMashhad University of Medical SciencesMashhadIran
  3. 3.Cardiovascular Research Center, School of MedicineMashhad University of Medical SciencesMashhadIran
  4. 4.Guy Hilton Research Centre, Institute for Science and Technology in MedicineUniversity of KeeleStoke on TrentUK

Personalised recommendations